ExeVir pulls in $50m Series A

ExeVir, a developer of single domain antibody therapies, has raised $50 million in Series A financing.

ExeVir, a developer of single domain antibody therapies, has raised $50 million in Series A financing. Fund+ led the round with participation from other investors that included VIB, UCB Ventures, SFPI-FPIM, V-Bio Ventures, SRIW, Noshaq, Vives IUF, SambrInvest and several Belgian family offices.

Source: Press Release